Ofloxacin, a new quinolone in the treatment of genitourinary and enteric infections.
During 1984 to 1986, 121 patients with gonorrhoea were treated with ofloxacin. This report is to summarize the results of our trial in patients treated with three different dose regimens of ofloxacin: A) a single 800 mg dose of ofloxacin (32 patients); B) a single 400 mg dose of ofloxacin (55 patients) or C) a twice a day dose of 600 mg ofloxacin (34 patients). In addition, 19 patients with urinary tract infection and eight patients with enteric fever were treated with 400 mg ofloxacin twice a day for seven to ten days. Out of 121 patients with gonococcal urethritis, only 107 patients were evaluable. Cure was obtained in 96.5%; 93.2% and 94.5% of the patients in groups A, B and C respectively. 16 out of 17 patients with urinary tract infection achieved clinical cure or improvement. The 16 patients were bacteriologically accessible; pathogens were eradicated in all of them. Ofloxacin was also effective in the treatment of enteric fever, in which eradication was achieved in all seven patients. 28% of Neisseria gonorrhoea and 29% of Salmonella spp. isolated in our community were beta-lactamase-positive.